Over the past ten years, artificial intelligence methods have largely supplanted classical computer vision techniques for applications ranging from facial recognition to written character translation to medical image interpretation. These methods provide significant advantages in terms of implementation speed, flexibility and accuracy. However, there are also potential pitfalls associated with AI approaches that must be understood to be avoided. This talk will discuss classical methods for automated image interpretation and will contrast them with the AI techniques that have largely replaced them, while providing a general overview of what these algorithms are, how they are implemented and how they function.
This webinar is Part 3 of a series on Imaging in Oncology:
Click here for Part 1: Advanced Imaging in Oncology (upcoming on Nov 2/21)
Click here for Part 2: Assessing Imaging Outcomes in Immune Oncology (upcoming on Nov 3/21)
Edward Ashton, PhD, VP, Oncology Imaging, Philips BioTel Research
Ed Ashton serves as the Vice President of Oncology Imaging for Philips BioTel Research. In this role, he has provided technical leadership on more than 200 clinical trials in oncology, neurology, and cardiology over the past twenty years. Dr. Ashton is a frequent speaker at international imaging conferences, and has authored many peer-reviewed publications describing his research. Prior to joining BioTel Research, Dr. Ashton was a lead signal processing engineer at The MITRE Corporation in McLean, VA. Earlier in his career, he spent three years as a research engineer with the Naval Research Laboratory, where he received the Alan Berman Research Publication Award and was nominated for the Edison Award for Applied Science.Message Presenter
Who Should Attend?
This webinar will benefit medical and non-medical professionals in the biopharmaceutical industry, especially those with a general interest in automation, and a specific interest in the interpretation of medical images in a clinical trial setting.
Philips BioTel Research
Philips BioTel Research is an industry leader in medical imaging and cardiovascular safety testing for clinical trials. Philips BioTel Research offers global operational support for cardiovascular monitoring in all therapeutic areas, and advanced imaging services in oncology, cardiovascular, metabolic, musculoskeletal, neurologic, and medical device studies. Their experienced research team comprises key opinion leaders, board-certified cardiologists and radiologists, sub-specialty scientists, and highly trained technicians — who acquire, evaluate, and report high-quality data through an efficient, cloud-based infrastructure. Many biopharmaceutical trial sponsors rely on our scientific leaders to help design and optimize their protocols and statistical analysis plans. We have conducted clinical trials contributing to the market approval of nearly 100 new drugs to date.